Endocrine System Diseases  >>  Triapine (3-AP)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Triapine (3-AP) / Vion, Northwestern University
NCT00078975: 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

Completed
2
26
Canada
gemcitabine hydrochloride, triapine
University Health Network, Toronto, National Cancer Institute (NCI)
Pancreatic Cancer
12/05
01/09
NCT00085371: Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Completed
2
116
US
triapine
National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
07/06
 
NCT00064051: 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Completed
2
US, Europe
gemcitabine hydrochloride, triapine
Vion Pharmaceuticals
Pancreatic Cancer
08/06
08/08
NCT00081276: 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Completed
2
48
US
triapine, 3-AP, OCX-191, cisplatin, CACP, CDDP, CPDD, DDP, laboratory biomarker analysis
National Cancer Institute (NCI)
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
01/07
 

Download Options